Business
Corbus Pharmaceuticals Holdings, Inc.: For example, aspects of our proprietary technology platform are based on unpatented trade secrets and know-how related to the manufacturing of our product candidates.
Net loss widened 95.3% to $78.5M, while Operating cash flow decreased 54.3% to −$64.5M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net loss $78.5MWatch
- Cash generation — Free cash flow −$64.5MNote
- Insiders — 0 buys; 11 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Leadership changes
From Corbus Pharmaceuticals Holdings, Inc.'s own filings, the day they're filed.
- Alan Holmer · Directors · departureeff. 2025-12-31
- Ian Hodgson · Chief Operating Officer · appointmenteff. 2025-03-15
- Winston W. Kung · departureeff. 2024-08-16
Latest filings
- 8-K · Company announcement2026-10-15
- 8-K · Company announcement2026-09-14
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Corbus Pharmaceuticals Holdings, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.